Key Takeaway: The FDA is developing a “plausible mechanism framework” to facilitate approval of individualized therapies for the treatment of rare genetic diseases that currently face approval challenges.
As discussed previously (“New FDA Guidance Allows Biosimilar Applicants to Use Data From Outside the U.S. To Accelerate Their Approval in the U.S.”), the U.S. Food and Drug Administration (FDA) is embracing regulatory flexibility in order to accelerate approval of biologic and biosimilar treatments. Provided here is a further discussion of the draft guidance issued on February 23, 2026, which is aimed at helping developers of individualized therapies for rare genetic diseases gain approval when randomized controlled trials are not possible due to small patient populations. [1]
Recent technological advances now make it possible to identify the genetic changes underlying rare debilitating and/or life-threatening diseases and to develop individualized targeted therapies. Recognizing the need for regulatory flexibility to both encourage scientific investment and accelerate patient access, the FDA has developed a “plausible mechanism framework” to provide guidance for generating sufficient data to demonstrate that a drug or biological product is safe and effective for the intended use and that the product can be manufactured to regulatory quality standards.[1]
For the purposes of this guidance, individualized therapies are considered therapies that target a specific pathophysiologic abnormality serving as the root cause of a disease, for example, specific pathogenic genetic variants causing a severely debilitating or life-threatening disease.[2]
Application of the plausible mechanism framework involves:
- Identifying the disease-causing abnormality.
- Developing a therapy that targets the root cause or proximate biological alteration.
- Relying on well-characterized natural history data in untreated patients.
- Confirming successful target drugging and/or editing.
- Demonstrating improvement in clinical outcomes or disease course.[3]
Given the small numbers of patients expected to be treated, the FDA expects that the first-in-human clinical investigations that will open investigational new drug (IND) applications will also be the primary sources of evidence to support approvals. Therefore, the FDA recommends designing protocols that are well-controlled and adequate to generate sufficient confirmatory evidence.[4] The FDA also recommends that sponsors discuss their proposed nonclinical development programs[5] and chemistry, manufacturing, and controls (CMC) development[6] with the Agency early in development to seek feedback on leveraging proof-of-concept and safety data in the approval process.
Finally, while the FDA’s guidance specifically discusses genome editing and RNA-based therapies, it leaves room for other types of individualized therapies when clinical evidence from a limited number of patients will be available to support the product’s safety and efficacy in the intended patient population.[7]
The Guidance is open for comments until April 27, 2026 [3].
Editor: Brenden S. Gingrich, Ph.D.
[1] See https://www.fda.gov/media/191247/download at page 1, lines 17-23
[2] See https://www.fda.gov/media/191247/download at pages 1-2, lines 34-38
[3] See https://www.fda.gov/media/191247/download at page 1, lines 23-32
[4] See https://www.fda.gov/media/191247/download at page 12, lines 418-437; for further discussion of design of clinical investigations, see pages 13-14, lines 459-497
[5] See https://www.fda.gov/media/191247/download at pages 7-8, lines 209-254
[6] See https://www.fda.gov/media/191247/download at pages 17-20, lines 634-728
[7] See https://www.fda.gov/media/191247/download at page 2, lines 40-44
Subscribe for News and Updates
